On June 25, 2018 Andarix Pharmaceuticals, a clinical stage company aimed at developing a targeted peptide therapies for hard to treat cancers, reported that it will present a poster at the Metals in Medicine Gordon Research Conference (Press release, Andarix Pharmaceuticals, JUN 25 2018, View Source [SID1234527792]) .The conference will take place June 25-29 in Andover, NH.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The theme of the conference is: The Indispensable Role of Metals in Medical Diagnostics, Therapeutics and Beyond. Andarix will be presenting clinical findings pertaining to Tozaride, a Rhenium metal-based drug developed by the company. The conference is an opportunity for Andarix to present its innovative technology to world
leading scientists and international metal-science experts.

About Tozaride
Tozaride is a novel, best-in-class therapeutic for lung and other cancers, which is based on a radio-labeled somatostatin peptide. Early clinical studies demonstrated that Tozaride is well tolerated and that treatment can promote disease stabilization and improve overall survival in heavily pre-treated advanced lung cancer patients. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield
significant clinical benefits for both small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC) patients. This therapeutic stands to provide an additional treatment option for patients who are not eligible for, or who have not responded to current therapies.